^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CAP-0121

    i
    Other names: CAP-0121
    Company:
    Califia Pharma
    Drug class:
    DNA damage stimulant
    2years
    Preclinical evaluation of CAP-0121 for multidrug resistant cancers (AACR 2022)
    This response of CAP-0121 in drug resistant xenografts is observed at nontoxic doses. Synergistic action is observed when CAP-0121 is administered in combination with traditional drugs used for treating ovarian cancer, including taxanes, platinum agents, and PARP inhibitors.
    Preclinical
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1)
    |
    CAP-0121 • irofulven-1 (LP-100)